Investment in associates (Tables)
|
4 Months Ended |
12 Months Ended |
Aug. 31, 2024 |
Mar. 31, 2024 |
| IfrsStatementLineItems [Line Items] |
|
|
| Schedule of financial information represents the amount in the financial statements |
The
following table analyses the financial assets and liabilities in the statement of financial position by the class of financial instruments
to which they are assigned, and therefore by the measurement basis:
Schedule of financial assets and liabilities
| | |
2024 | |
| | |
USD | |
| Financial
assets | |
| | |
| At
amortised cost | |
| | |
| Cash
on hand | |
| 1 | |
| Financial
liabilities | |
| | |
| At
amortised cost | |
| | |
| Other
payable and accrued expense | |
| 6,303 | |
|
|
| Alps Global Holding Berhad [Member] |
|
|
| IfrsStatementLineItems [Line Items] |
|
|
| Schedule of investment in associates |
|
Schedule
of investment in associates
| | |
| | | |
| | |
| | |
2024 | | |
2023 | |
| | |
USD | | |
USD | |
| | |
| | |
| |
| Unquoted shares - at cost | |
| | | |
| | |
| As at 1 April | |
| 895 | | |
| 221 | |
| Unquoted shares - at cost beginning | |
| 895 | | |
| 221 | |
| Addition during the financial year | |
| 1,492,955 | | |
| 674 | |
| | |
| | | |
| | |
| As at 31 March | |
| 1,493,850 | | |
| 895 | |
| Unquoted shares - at cost end | |
| 1,493,850 | | |
| 895 | |
| | |
| | | |
| | |
| Less: Accumulated impairment loss | |
| | | |
| | |
| As at 1 April | |
| (257 | ) | |
| (7 | ) |
| Accumulated impairment loss beginning | |
| (257 | ) | |
| (7 | ) |
| Addition during the financial year | |
| - | | |
| (250 | ) |
| | |
| | | |
| | |
| As at 31 March | |
| (257 | ) | |
| (257 | ) |
| Accumulated impairment loss end | |
| (257 | ) | |
| (257 | ) |
| | |
| | | |
| | |
| Unquoted shares - at cost, net | |
| 1,493,593 | | |
| 638 | |
| | |
| | | |
| | |
| Share of post-acquisition reserve | |
| | |
| |
| As at 1 April | |
| 10,490 | | |
| 8,855 | |
| Share of post-acquisition reserve beginning | |
| 10,490 | | |
| 8,855 | |
| Share of profit during the financial year | |
| 3,421 | | |
| 1,635 | |
| | |
| | | |
| | |
| As at 31 March | |
| 13,911 | | |
| 10,490 | |
| Share of post-acquisition reserve beginning | |
| 13,911 | | |
| 10,490 | |
| | |
| | | |
| | |
| Share of post-acquisition reserve, net | |
| 1,507,504 | | |
| 11,128 | |
| Exchange differences | |
| (860 | ) | |
| (414 | ) |
| | |
| | | |
| | |
| Investment
in associates | |
| 1,506,644 | | |
| 10,714 | |
|
| Schedule of details of associates |
|
The
details of associates are as follows:
Schedule of details of associates
| |
|
|
|
Effective
equity |
|
|
| |
|
Place
of |
|
interest |
|
|
| Name
of Company |
|
incorporation |
|
2024 |
|
2023 |
|
Principal
activities |
| |
|
|
|
% |
|
% |
|
|
| Vax
Biotech Sdn. Bhd. (“Vax Biotech”) |
|
Malaysia |
|
30.0 |
|
30.0 |
|
Manufacture
of medicaments |
| |
|
|
|
|
|
|
|
|
| Alps
Globemedics Sdn. Bhd. (“Alps Globemedics”) |
|
Malaysia |
|
29.0 |
|
29.0 |
|
Marketing
of health and beauty product and services |
| |
|
|
|
|
|
|
|
|
| Cilo Cybin Holdings Limited (“Cilo Cybin”) |
|
South Africa |
|
40.5 |
|
- |
|
Investment in biotech, biohacking and pharmaceutical businesses |
|
| Schedule of financial information represents the amount in the financial statements |
|
Schedule
of financial information represents the amount in the financial statements
| | |
2024 | | |
2023 | |
| | |
USD | | |
USD | |
| | |
| | |
| |
| Statement of financial position | |
| | | |
| | |
| Current assets, representing total assets | |
| 3,354,690 | | |
| - | |
| | |
| | | |
| | |
| Current liabilities, representing total liabilities | |
| (593,538 | ) | |
| - | |
| | |
| | | |
| | |
| Net assets of the associate | |
| 2,761,152 | | |
| - | |
| | |
| | | |
| | |
| Statement of comprehensive income | |
| | | |
| | |
| Profit for the financial period | |
| 21,809 | | |
| - | |
| | |
| | | |
| | |
| Share of profit of the associate | |
| 8,742 | | |
| - | |
|
| Alps Global Holding Berhad [Member] | Vax Biotech Sdn Bhd [member] |
|
|
| IfrsStatementLineItems [Line Items] |
|
|
| Schedule of financial information represents the amount in the financial statements |
|
Schedule
of financial information represents the amount in the financial statements
| | |
2024 | | |
2023 | |
| | |
USD | | |
USD | |
| | |
| | |
| |
| Statement of financial position | |
| | | |
| | |
| Current assets, representing total assets | |
| 686 | | |
| 1,815 | |
| | |
| | | |
| | |
| Current liabilities, representing total liabilities | |
| (2,596 | ) | |
| (2,653 | ) |
| | |
| | | |
| | |
| Net assets of the associate | |
| (1,910 | ) | |
| (838 | ) |
| | |
| | | |
| | |
| Statement of comprehensive income | |
| | | |
| | |
| Expenses for the financial year | |
| (1,147 | ) | |
| (1,144 | ) |
| | |
| | | |
| | |
| Loss for the financial year | |
| (1,147 | ) | |
| (1,144 | ) |
| | |
| | | |
| | |
| Share of loss of the associate | |
| (344 | ) | |
| (343 | ) |
|
| Schedule of financial information to the carrying amount of interest |
|
Schedule
of financial information to the carrying amount of interest
| | |
2024 | | |
2023 | |
| | |
USD | | |
USD | |
| | |
| | |
| |
| Proportion of net assets of the associate | |
| 155 | | |
| 82 | |
| Exchange differences | |
| (84 | ) | |
| 3 | |
| | |
| | | |
| | |
| Carrying amount of the Group’s interest in associate | |
| 71 | | |
| 85 | |
|
| Alps Global Holding Berhad [Member] | Alps Globemedics Sdn Bhd [member] |
|
|
| IfrsStatementLineItems [Line Items] |
|
|
| Schedule of financial information represents the amount in the financial statements |
|
Schedule
of financial information represents the amount in the financial statements
| | |
2024 | | |
2023 | |
| | |
USD | | |
USD | |
| | |
| | |
| |
| Statement of financial position | |
| | | |
| | |
| Non-current assets | |
| 3,377 | | |
| 4,111 | |
| Current assets | |
| 28,413 | | |
| 34,602 | |
| | |
| | | |
| | |
| Total assets | |
| 31,790 | | |
| 38,713 | |
| | |
| | | |
| | |
| Non-current liabilities | |
| (759 | ) | |
| (813 | ) |
| Current liabilities | |
| (14,263 | ) | |
| (2,469 | ) |
| | |
| | | |
| | |
| Total liabilities | |
| (15,022 | ) | |
| (3,282 | ) |
| | |
| | | |
| | |
| Net assets of the associate | |
| 16,768 | | |
| 35,431 | |
| Statement of comprehensive income | |
| | | |
| | |
| Revenue for the financial year | |
| 120,942 | | |
| 138,416 | |
| | |
| | | |
| | |
| (Loss)/Profit for the financial year | |
| (16,590 | ) | |
| 6,593 | |
| | |
| | | |
| | |
| Share of (loss)/profit of the associate | |
| (4,977 | ) | |
| 1,978 | |
|
| Schedule of financial information to the carrying amount of interest |
|
Schedule
of financial information to the carrying amount of interest
| | |
2024 | | |
2023 | |
| | |
USD | | |
USD | |
| | |
| | |
| |
| Proportion of net assets of the associate | |
| 5,652 | | |
| 11,046 | |
| Exchange differences | |
| (622 | ) | |
| (417 | ) |
| | |
| | | |
| | |
| Carrying amount of the Group’s interest in associate | |
| 5,030 | | |
| 10,629 | |
|